ArticleEuropean journal of ophthalmology2026

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid.

Ricardo García-Serrano Fuertes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.